Scott H Okuno

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck
    Scott H Okuno
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer 94:2224-31. 2002
  2. doi request reprint A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021
    Scott H Okuno
    Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer 112:1772-9. 2008
  3. ncbi request reprint Evaluation of epothilone B analog in advanced soft tissue sarcoma: a phase II study of the phase II consortium
    Scott Okuno
    Mayo Clinic College of Medicine, 200 First St, Southwest, Medical Oncology, Rochester, MN 55905, USA
    J Clin Oncol 23:3069-73. 2005
  4. ncbi request reprint The enigma of desmoid tumors
    Scott Okuno
    Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Treat Options Oncol 7:438-43. 2006
  5. ncbi request reprint Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): a trial of the Eastern Cooperative Oncology Group
    Scott Okuno
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 97:1969-73. 2003
  6. pmc A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C)
    Scott Okuno
    Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Cancer 117:3468-75. 2011
  7. ncbi request reprint Mammalian target of rapamycin inhibitors in sarcomas
    Scott Okuno
    Medical Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Curr Opin Oncol 18:360-2. 2006
  8. ncbi request reprint Combination chemotherapy for desmoid tumors
    Scott H Okuno
    Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 97:1134-5. 2003
  9. ncbi request reprint Phase II trial of gemcitabine in advanced sarcomas
    Scott Okuno
    Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Cancer 94:3225-9. 2002
  10. ncbi request reprint Small cell lung cancer: current therapy and promising new regimens
    Scott H Okuno
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Oncologist 7:234-8. 2002

Detail Information

Publications39

  1. ncbi request reprint Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck
    Scott H Okuno
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer 94:2224-31. 2002
    ..This study was undertaken to assess the antitumor activity and toxicity profile of the drug combination methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) in this patient population...
  2. doi request reprint A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021
    Scott H Okuno
    Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer 112:1772-9. 2008
    ....
  3. ncbi request reprint Evaluation of epothilone B analog in advanced soft tissue sarcoma: a phase II study of the phase II consortium
    Scott Okuno
    Mayo Clinic College of Medicine, 200 First St, Southwest, Medical Oncology, Rochester, MN 55905, USA
    J Clin Oncol 23:3069-73. 2005
    ..This study was performed to determine the activity of BMS-247550 in patients with soft tissue sarcomas (STSs) who had not received prior chemotherapy for metastatic disease...
  4. ncbi request reprint The enigma of desmoid tumors
    Scott Okuno
    Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Treat Options Oncol 7:438-43. 2006
    ..As more options become available, selecting the correct therapy becomes more nuanced. Further clinical trials are needed to help the clinician navigate his or her way through the morass of desmoid tumor therapies...
  5. ncbi request reprint Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): a trial of the Eastern Cooperative Oncology Group
    Scott Okuno
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 97:1969-73. 2003
    ..The current study was conducted to evaluate the antitumor activity and toxicity of gemcitabine in patients with advanced sarcoma...
  6. pmc A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C)
    Scott Okuno
    Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Cancer 117:3468-75. 2011
    ..The primary goal of this trial was to evaluate the confirmed response rate of temsirolimus (CCI-779), a mammalian target of rapamycin in patients with advanced soft tissue sarcomas (STS)...
  7. ncbi request reprint Mammalian target of rapamycin inhibitors in sarcomas
    Scott Okuno
    Medical Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Curr Opin Oncol 18:360-2. 2006
    ..The mammalian target of rapamycin plays a central role in cell growth, proliferation, and apoptosis and its inhibition has demonstrated antitumor activity in many tumors and shows promise against sarcomas...
  8. ncbi request reprint Combination chemotherapy for desmoid tumors
    Scott H Okuno
    Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 97:1134-5. 2003
    ..The use of chemotherapy also has been reported to have activity...
  9. ncbi request reprint Phase II trial of gemcitabine in advanced sarcomas
    Scott Okuno
    Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Cancer 94:3225-9. 2002
    ..Gemcitabine, a nucleoside antimetabolite, is an analog of deoxycytidine that has shown antitumor activity in several tumors. The aim of the current study was to determine the clinical activity of gemcitabine in patients with sarcomas...
  10. ncbi request reprint Small cell lung cancer: current therapy and promising new regimens
    Scott H Okuno
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Oncologist 7:234-8. 2002
    ..In this review, we cover current therapy and promising new regimens and highlight areas where improvement is needed in the management of small cell lung cancer...
  11. ncbi request reprint Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer
    Yolanda I Garces
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 67:995-1001. 2007
    ..The primary goal was to identify the maximum tolerable dose (MTD) of thoracic radiation therapy (TRT) that can be given with chemotherapy and amifostine for patients with limited-stage small-cell lung cancer (LSCLC)...
  12. ncbi request reprint A pilot study of high-dose intraarterial cisplatin chemotherapy with concomitant accelerated radiotherapy for patients with previously untreated T4 and selected patients with T3N0-N3M0 squamous cell carcinoma of the upper aerodigestive tract
    Robert L Foote
    Division of Radiation Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Cancer 103:559-68. 2005
    ....
  13. doi request reprint Surgical approach and oncologic outcomes following multidisciplinary management of retrorectal sarcomas
    Eric J Dozois
    Division of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN, USA
    Ann Surg Oncol 18:983-8. 2011
    ..Retrorectal sarcomas are rare, and limited data are available on oncologic outcomes following surgery. Our aim was to evaluate outcomes in this patient population at our institution...
  14. ncbi request reprint Informed consent in advanced laryngeal cancer
    Robert L Foote
    Department of Radiation Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Head Neck 29:230-5. 2007
    ..This study was designed to evaluate the relationship between the informed consent process and the treatment received by patients with advanced laryngeal cancer...
  15. ncbi request reprint Organ preservation for advanced laryngeal carcinoma
    Robert L Foote
    Department of Radiation Oncology, Mayo Clinic College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Head Neck 28:689-96. 2006
    ..Inclusion of patients with mobile vocal cords on larynx preservation trials may lead to overstatement of larynx preservation (LPR) and survival (OS) rates...
  16. ncbi request reprint Chemotherapy in the management of advanced cutaneous squamous cell carcinoma in organ transplant recipients: theoretical and practical considerations
    Juan Carlos Martinez
    Mayo Medical School, Rochester, Minnesota 55905, USA
    Dermatol Surg 30:679-86. 2004
    ..Advances in the use of chemotherapy in metastatic head and neck squamous cell carcinoma (HNSCC) may be applicable to this increasingly common disease...
  17. ncbi request reprint Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial
    Kostandinos Sideras
    Division of Hematology, Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 81:758-67. 2006
    ..To prospectively assess whether low-molecular-weight heparin (LMWH) provides a survival benefit in patients with advanced cancer...
  18. pmc Quality of life and symptom burden among long-term lung cancer survivors
    Ping Yang
    Mayo Clinic, College of Medicine, Rochester, Minnesota 55905, USA
    J Thorac Oncol 7:64-70. 2012
    ..The primary aim of this study was to conduct a 7-year longitudinal study in survivors of primary lung cancer which identified factors associated with either decline or improvement in QOL over time...
  19. doi request reprint Malignant primary cardiac tumors: review of a single institution experience
    Lijo Simpson
    Division of Medical Oncology, Mayo Clinic Cancer Center, Mayo Clinic, Rochester, MN 55905, USA
    Cancer 112:2440-6. 2008
    ..Primary cardiac sarcomas are uncommon. The authors undertook to review the Mayo Clinic's experience with primary cardiac sarcomas consisting of 34 patients seen over a 32-year period...
  20. ncbi request reprint Histologic grade is an independent prognostic factor for survival in non-small cell lung cancer: an analysis of 5018 hospital- and 712 population-based cases
    Zhifu Sun
    Division of Epidemiology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    J Thorac Cardiovasc Surg 131:1014-20. 2006
    ..Our objective was to determine whether histologic grade independently contributes to the prognosis of non-small cell lung cancer...
  21. ncbi request reprint A phase II study of the dolastatin 15 analogue LU 103793 in the treatment of advanced non-small-cell lung cancer
    Randolph S Marks
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Am J Clin Oncol 26:336-7. 2003
    ..Forty-two treatment cycles were administered with relatively modest toxicity. No responses were seen. This agent appears to be inactive in the treatment of advanced non-SCLC...
  22. doi request reprint Adjuvant chemoradiation therapy with high-dose versus weekly cisplatin for resected, locally-advanced HPV/p16-positive and negative head and neck squamous cell carcinoma
    Jessica L Geiger
    Department of Internal Medicine, Mayo Clinic, Rochester, MN, United States
    Oral Oncol 50:311-8. 2014
    ..This study compares the outcomes of patients with locally-advanced HPV-negative HNSCC and HPV/p16-positive oropharynx HNSCC treated with adjuvant chemoradiation therapy with either high-dose or weekly cisplatin...
  23. doi request reprint Role of operative therapy in treatment of metastatic gastrointestinal stromal tumors
    Victor Zaydfudim
    Division of Gastroenterologic and General Surgery, Mayo Clinic, Rochester, Minnesota, USA
    J Surg Res 177:248-54. 2012
    ..Current treatment strategies rely on the response to tyrosine kinase inhibitors (TKIs), with resultant individualization of operative intervention. We investigated the role of operative therapy in patients with metastatic GIST...
  24. doi request reprint Angiosarcoma: a study of 98 cases with immunohistochemical evaluation of TLE3, a recently described marker of potential taxane responsiveness
    Wonwoo Shon
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
    J Cutan Pathol 38:961-6. 2011
    ..Our study confirms the poor prognosis of angiosarcoma. Vasoformative angiosarcoma may have a more favorable prognosis. A lack of TLE3 expression in cutaneous angiosarcoma may reflect differing pathogenesis...
  25. ncbi request reprint Dedifferentiated chondrosarcoma: the role of chemotherapy with updated outcomes
    Ian D Dickey
    Department of Orthopedic Surgery, Mayo Clinic College of Medicine, 200 First Street S W, Med Sci 3 69, Rochester, MN 55905, USA
    J Bone Joint Surg Am 86:2412-8. 2004
    ..The current study examines the influence of advancements in imaging and chemotherapy on outcome and serves as an extension to a previous study published in 1986...
  26. ncbi request reprint A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer
    Grace K Dy
    Department of Oncology, Division of Medical Oncology, Mayo Clinic and Foundation, 200 First St SW, Rochester, MN 55905, USA
    Cancer Chemother Pharmacol 56:623-8. 2005
    ....
  27. ncbi request reprint Causes and outcomes of spontaneous pneumothoraces in solid tumor cancer patients: an update for the medical oncologist
    S Ni Chan
    Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Thorac Oncol 1:335-8. 2006
    ..A dearth of present day information on this entity in solid tumor cancer patients prompted this single-institution retrospective study on current causes and outcomes...
  28. ncbi request reprint Swallow function in patients before and after intra-arterial chemoradiation
    Darlene E Graner
    Department of Neurology, Division of Radiation Oncology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA
    Laryngoscope 113:573-9. 2003
    ..To prospectively evaluate swallow function in patients with advanced head and neck cancer before and after completion of intra-arterial chemoradiation therapy and planned neck dissection...
  29. doi request reprint Neurogenic tumors of the pelvis: clinicopathologic features and surgical outcomes using a multidisciplinary team
    Eric J Dozois
    Division of Colon and Rectal Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Ann Surg Oncol 16:1010-6. 2009
    ..Few data exist regarding the outcomes in patients undergoing surgery for pelvic tumors of neurogenic origin. Our aim was to characterize the clinical and pathologic features of pelvic neurogenic tumors and assess surgical outcomes...
  30. doi request reprint Resection of a giant primary synovial sarcoma of the inferior vena cava extending into the right atrium with caval reconstruction under cardiopulmonary bypass and circulatory arrest
    Kevin B Wise
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Perspect Vasc Surg Endovasc Ther 24:95-101. 2012
    ..Synovial sarcoma primarily arises in para-articular locations of the extremities. However, numerous unique sites of origin have been reported. There are only 5 known cases of primary intravascular synovial sarcoma...
  31. ncbi request reprint Effect of granulocyte-stimulating factors on marrow of adult patients with musculoskeletal malignancies: incidence and MRI findings
    Robert P Hartman
    Department of Radiology, Mayo Clinic, 200 1st St SW, Rochester, MN 55902, USA
    AJR Am J Roentgenol 183:645-53. 2004
    ....
  32. ncbi request reprint Glutamine does not prevent paclitaxel-associated myalgias and arthralgias
    Stacy D Jacobson
    Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Support Oncol 1:274-8. 2003
    ..96). Thus this trial did not suggest any role for oral glutamine, compared with placebo, for preventing the development, or alleviating the severity, of paclitaxel-induced myalgias/arthralgias...
  33. ncbi request reprint Intratumoral administration of a 1,2-dimyristyloxypropyl-3- dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma
    Evanthia Galanis
    Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Cancer 101:2557-66. 2004
    ..In the current study, the authors investigated the safety and efficacy of in situ vaccination with Leuvectin in patients with metastatic renal cell carcinoma...
  34. ncbi request reprint Clinical, pathologic, and immunohistochemical characteristics of gastrointestinal stromal tumors of the colon and rectum: implications for surgical management and adjuvant therapies
    Imran Hassan
    Division of Colon and Rectal Surgery, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA
    Dis Colon Rectum 49:609-15. 2006
    ....
  35. ncbi request reprint Ramifications of severe organ dysfunction in newly diagnosed patients with small cell lung cancer: contemporary experience from a single institution
    Karin F Giordano
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Lung Cancer 49:209-15. 2005
    ....
  36. ncbi request reprint Skp2 protein expression in soft tissue sarcomas
    Andre M Oliveira
    Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Clin Oncol 21:722-7. 2003
    ..The expression and prognostic role of Skp2 in a large series of soft tissue sarcomas has not been previously investigated...
  37. ncbi request reprint Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis
    Imran Hassan
    Division of Colon and Rectal Surgery, SIU School of Medicine, 701 N Rutledge, PO Box 19638, Springfield, IL, 67308, USA
    Ann Surg Oncol 15:52-9. 2008
    ..We performed a comparative and prognostic analysis of our experience with surgically managed GIST to determine factors associated with adverse oncologic outcomes...
  38. ncbi request reprint Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]
    Robert G Maki
    Department of Medicine, Memorial Sloan Kettering Cancer Center New York, NY 10021, USA
    J Clin Oncol 25:2755-63. 2007
    ..To determine if the addition of docetaxel to gemcitabine improved clinical outcome of patients with metastatic soft tissue sarcomas, we compared a fixed dose rate infusion of gemcitabine versus a lower dose of gemcitabine with docetaxel...
  39. ncbi request reprint Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma
    Howard H Bailey
    University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
    Cancer 107:2462-7. 2006
    ....